Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied

Novo Nordisk is grappling with sustained competition from copycat Wegovy drugs made by compounding pharmacies and rival Eli Lilly, which led to a recent profit warning, a $95 billion market value loss, and a 30% stock plunge. The company now anticipates no reduction in compounding this year, despite earlier FDA actions, forcing a second cut to its 2025 sales growth forecast to 8-14% and contributing to Q2 sales missing initial expectations. With a new CEO taking over, Novo Nordisk is pursuing lawsuits against compounders and focusing on cost efficiencies amid growing investor concerns about its long-term competitiveness in the rapidly evolving weight-loss drug market.

Analysis

Novo Nordisk is confronting a significant and persistent challenge from compounded, copycat versions of its Wegovy obesity drug, which has materially altered its financial trajectory. The issue directly triggered a recent profit warning that erased $95 billion from its market value and caused a 30% stock decline, the worst weekly performance in over two decades. The company's management has reversed its earlier expectation that an FDA ban would curtail compounding; the CFO now confirms the revised outlook does not assume any reduction in the over one million U.S. patients using these alternatives this year. This has forced a second downward revision of its 2025 sales growth forecast to 8-14% from a prior 13-21%. While second-quarter Wegovy sales grew 67% and EBIT increased 29% year-over-year, total company revenue of 76.86 billion Danish crowns missed initial analyst expectations. Compounding these pressures, analysts at Barclays anticipate deeper price erosion in the key U.S. market in the second half of the year due to channel mix and higher rebates. In response, the company is pursuing legal action against compounders and, under a newly appointed CEO, is pivoting towards a strategy of 'savings and efficiencies' to protect its cost base, signaling a defensive shift amid mounting investor and analyst concerns.

Key Decisions for Investors

• Investors should closely monitor the efficacy of Novo Nordisk's legal actions and any further regulatory updates regarding compounded GLP-1 drugs, as this is the primary driver of the revised, lower sales guidance.
• Given the recent 30% share price decline and multiple analyst downgrades, it is prudent to re-evaluate the company's valuation in light of the new 8-14% sales growth forecast and anticipated U.S. pricing pressure.
• The persistent challenges for Wegovy could present a strategic advantage for competitor Eli Lilly, suggesting a potential portfolio rebalancing towards rivals with a clearer near-term growth path.
• Pay close attention to early signals from the new CEO regarding the scale and impact of the announced cost-cutting program, as successful margin protection will be critical amidst slowing revenue growth.